ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

Summary

This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion ( compared to placebo), 250mcg/day on majore outcomes up to 6 months after randomization in participants with advanced HF with reduced ejection fraction(HFrEF).

Timeline

Start

2026-10

Primary completion

2029-11

Completion

2030-12

Drugs

Indications